Surveillance of Acutely Ill Adults with Respiratory Viruses, including SARS-CoV-2

Posting amdndment 0003 and updated Q&A

Posting amendment 0002 and updated Q&A

Posting amendment 0001 and updated Q&A

Posting Q&A

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to award a contract to provide a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).  The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations.  As RSV vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations.  VE estimates will include effectiveness against emerging variants of concern and duration of protection.  These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation.  Optional work is included to evaluate potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV, and influenza.  

See attached solicitation.

The period of performance is as follows:

Base Period: 09/01/2022 - 08/31/2023

Option Period 1: 09/01/2023 - 08/31/2024

Option Period 2: 09/01/2024 - 08/31/2025

Any questions regarding this notice shall be submitted in writing to Mark Draluck at syq1@cdc.gov in accordance with the procedures specified in the solicitation.  

Posting amendment 0002 and updated Q&A

Posting amendment 0001 and updated Q&A

Posting Q&A

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to award a contract to provide a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).  The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations.  As RSV vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations.  VE estimates will include effectiveness against emerging variants of concern and duration of protection.  These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation.  Optional work is included to evaluate potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV, and influenza.  

See attached solicitation.

The period of performance is as follows:

Base Period: 09/01/2022 - 08/31/2023

Option Period 1: 09/01/2023 - 08/31/2024

Option Period 2: 09/01/2024 - 08/31/2025

Any questions regarding this notice shall be submitted in writing to Mark Draluck at syq1@cdc.gov in accordance with the procedures specified in the solicitation.  

Posting amendment 0001 and updated Q&A

Posting Q&A

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to award a contract to provide a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).  The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations.  As RSV vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations.  VE estimates will include effectiveness against emerging variants of concern and duration of protection.  These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation.  Optional work is included to evaluate potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV, and influenza.  

See attached solicitation.

The period of performance is as follows:

Base Period: 09/01/2022 - 08/31/2023

Option Period 1: 09/01/2023 - 08/31/2024

Option Period 2: 09/01/2024 - 08/31/2025

Any questions regarding this notice shall be submitted in writing to Mark Draluck at syq1@cdc.gov in accordance with the procedures specified in the solicitation.  

Posting Q&A

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to award a contract to provide a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).  The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations.  As RSV vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations.  VE estimates will include effectiveness against emerging variants of concern and duration of protection.  These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation.  Optional work is included to evaluate potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV, and influenza.  

See attached solicitation.

The period of performance is as follows:

Base Period: 09/01/2022 - 08/31/2023

Option Period 1: 09/01/2023 - 08/31/2024

Option Period 2: 09/01/2024 - 08/31/2025

Any questions regarding this notice shall be submitted in writing to Mark Draluck at syq1@cdc.gov in accordance with the procedures specified in the solicitation.  

The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to award a contract to provide a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).  The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations.  As RSV vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations.  VE estimates will include effectiveness against emerging variants of concern and duration of protection.  These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation.  Optional work is included to evaluate potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV, and influenza.  

See attached solicitation.

The period of performance is as follows:

Base Period: 09/01/2022 - 08/31/2023

Option Period 1: 09/01/2023 - 08/31/2024

Option Period 2: 09/01/2024 - 08/31/2025

Any questions regarding this notice shall be submitted in writing to Mark Draluck at syq1@cdc.gov in accordance with the procedures specified in the solicitation.